Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products across wound care, eye care, dermatology, podiatry, animal health, and disinfectants, sold in over 55 countries. During the fiscal year ended March 31, 2026, the company achieved revenue growth through expanded distribution networks, entry into consumer markets, new product introductions, and regulatory clearances including FDA MoCRA registration and EU MDR certification. Key developments include retail launches with CVS and Walmart, new partnerships with Medline Industries and Personel & Covey, and product recognitions from the National Psoriasis Foundation and National Rosacea Society.
Segment Performance
The filing does not provide specific segment revenue or income figures broken down by business channel. However, the company reports overall revenue growth for fiscal year 2026 driven by expansion in distribution networks, consumer markets, and new product introductions. R&D expenses increased from $1,814,000 in fiscal 2025 to $2,271,000 in fiscal 2026. The company operates across six main channels (dermatology, eye care, wound care, podiatry, animal health care, and surface disinfectants) but does not disclose separate segment performance metrics in this excerpt.
Forward Guidance
The company states it "intends to continue to seek new regulatory clearances to expand potential markets for our products" and believes it "own[s] or have[s] access to sufficient factory space and equipment to produce an adequate amount of product to meet anticipated future requirements for at least the next two years." The filing contains forward-looking statement disclaimers noting "Our results could be materially different from our expectations because of various risks" but provides no specific financial targets or quantitative guidance.
Key Risk Factors
+8.2%
EPS (Basic)
-$1.89
+32.3%
EPS (Diluted)
-$1.89
+32.3%
Stockholders' Equity
$3.1M
-29.8%
The company faces significant competition from established pharmaceutical products including corticosteroids, topical steroids, and topical antibiotics in dermatology markets. Reliance on key customers for material revenue (customer C represented 15% of net revenues in fiscal 2026) creates concentration risk. Patent protection limitations present risks, as pending patent applications may not be issued and competitors could develop similar products or design around existing patents. Regulatory approval requirements across multiple jurisdictions and dependence on manufacturing capacity in Mexico present operational risks. The company's ability to maintain proprietary technology and prevent unauthorized use of intellectual property remains uncertain despite protective measures.
